New insider activity at Adverum Biotechnologies ( (ADVM) ) has taken place on May 17, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Laurent Fischer, the CEO, President, and Director of Adverum Biotechnologies, recently sold 9,126 shares of the company’s stock, amounting to a total transaction value of $18,252.
Recent Updates on ADVM stock
Adverum Biotechnologies recently reported a net loss of $47 million for Q1 2025, primarily due to high research and development and administrative costs as it advances its lead gene therapy candidate, Ixo-vec, for wet AMD, currently in Phase 3 trials. Despite financial challenges, the company is committed to its strategic focus on ocular gene therapies and plans another Phase 3 trial in late 2025. RBC Capital lowered Adverum’s price target from $5 to $4, citing financial overhang and the need for further de-risking, despite the ongoing pivotal study for wet AMD enrolling patients.
Spark’s Take on ADVM Stock
According to Spark, TipRanks’ AI Analyst, ADVM is a Neutral.
Adverum Biotechnologies faces significant financial and operational challenges, reflected in its low financial performance score. Technical indicators suggest bearish trends, and valuation metrics highlight speculative risks. The subtenant default situation exacerbates these concerns. Investors should be cautious, as the company needs to improve revenue generation and operational efficiencies to enhance its market position.
To see Spark’s full report on ADVM stock, click here.
More about Adverum Biotechnologies
YTD Price Performance: -57.29%
Average Trading Volume: 331,918
Technical Sentiment Signal: Sell
Current Market Cap: $43.03M